casirivimab/imdevimab (Ronapreve) for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding childrens) meta-analysis
Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 NCT04452318		RCT	casirivimab/imdevimab (Ronapreve)	placebo	COVID-19 prophylaxis (excluding childrens)	some concern	753/752	conclusif	demonstrated 83 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias statistically significant 2.0-fold increase in serious adverse events with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding childrens) meta-analysis